RPRX News & Events

Royalty Pharma provided an update on its business performance, including recent key accomplishments. Key highlights include: Royalty funding market reached record high of $10 billion in 2025, powered by synthetic royalties; Royalty Pharma maintained industry leadership with announced transactions of $4.7 billion; Multiple potential value-creating milestones expected across development-stage portfolio in 2026, including data readouts for daraxonrasib, litifilimab and pelacarsen

Royalty Pharma (RPRX) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries (TEVA), announced a funding agreement of up to $500M to accelerate the clinical development of Teva's anti-IL-15 antibody, TEV-'408. IL-15 is a key cytokine involved in multiple immune-mediated disease pathways. Emerging Phase 1b data from the ongoing TEV-'408 vitiligo study provides preliminary support for IL-15 as a potential therapeutic target to treat a broad variety of autoimmune conditions. Teva anticipates sharing results from TEV-'408 trials during 2026.